; (B) the wholesale acquisition cost per 30-day supply or typical course of treatment immediately prior to the price change; (C) the new wholesale acquisition cost per 30-day supply or typical course of treatment, when the change takes effect; and (D) financial and non-financial factors the manufacturer took into consideration when making the price change, including any changes or improvements to the drug. (c) Public database (1) In general The Secretary shall establish an internet-based system to post prescription drug information reported under subsection (a) and price change reports required under subsection (b). (2) Consumer subscription options The system established under paragraph (1) shall enable consumers to subscribe to price change notifications— (A) for— (i) all drugs; (ii) a particular drug; or (iii) a particular therapeutic class of drugs; and (B) that are limited to price changes that are at or over a specified amount. (3) Timing The prescription drug information reported under subsection (a) shall be made publicly available not later than 30 days after being reported to the Secretary. In the case of a price change report required under subsection (b), the Secretary shall make publicly available a notice of the price change contained in such report on the day such change takes effect. (d) Privacy protections The information submitted under subparagraphs (A) through (F) of subsection (a)(1) and paragraph (2)(A)(ii) shall be publicly available through the database established under subsection (c). No other information submitted to the Secretary pursuant to subsection (a) or (b) that is proprietary, confidential, or trade secret information shall be included in such database. (e) Definitions For purposes of this section— (1) the term manufacturer has the meaning given such term in section 581 of the Federal Food, Drug, and Cosmetic Act ( 21 U.S.C. 360eee )